Recent Insights into the Immunopathogenesis of Psoriasis Provide New Therapeutic Opportunities

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2004 Jun 17

PMID 15199399

Citations 131

Authors

Brian J Nickoloff

Frank O Nestle

Affiliations

Soon will be listed here.

Abstract

Chronic and excessive inflammation in skin and joints causes significant morbidity in psoriasis patients. As a prevalent T lymphocyte-mediated disorder, psoriasis, as well as the side effects associated with its treatment, affects patients globally. In this review, recent progress is discussed in the areas of genetics, the immunological synapse, the untangling of the cytokine web and signaling pathways, xenotransplantation models, and the growing use of selectively targeted therapies. Since psoriasis is currently incurable, new management strategies are proposed to replace previous serendipitous approaches. Such strategic transition from serendipity to the use of novel selective agents aimed at defined targets in psoriatic lesions is moving rapidly from research benches to the bedsides of patients with this chronic and debilitating disease.

Citing Articles

Phenotypical and biochemical characterization of murine psoriasiform and fibrotic skin disease models in Stabilin-deficient mice.

Krzistetzko J, Geraud C, Dormann C, Riedel A, Leibing T FEBS Open Bio. 2024; 14(9):1455-1470.

PMID: 38946049 PMC: 11492309. DOI: 10.1002/2211-5463.13857.

The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples.

Deigin V, Linkova N, Vinogradova J, Vinogradov D, Polyakova V, Medvedev D Int J Mol Sci. 2024; 25(9).

PMID: 38732260 PMC: 11084461. DOI: 10.3390/ijms25095042.

Recent Approaches for the Topical Treatment of Psoriasis Using Nanoparticles.

Bodnar K, Feher P, Ujhelyi Z, Bacskay I, Jozsa L Pharmaceutics. 2024; 16(4).

PMID: 38675110 PMC: 11054466. DOI: 10.3390/pharmaceutics16040449.

Theoretical Studies of DNA Microarray Present Potential Molecular and Cellular Interconnectivity of Signaling Pathways in Immune System Dysregulation.

Garcia J, Tayo L Genes (Basel). 2024; 15(4).

PMID: 38674328 PMC: 11049615. DOI: 10.3390/genes15040393.

Atypical Mycobacterial Infection Mimicking Psoriasis in an Elderly Patient: Diagnostic Challenges and Management.

Arshad M, Kumar A, Shafique Ur Rehman M, Tito Rodriguez P, Varrassi G Cureus. 2024; 16(1):e52139.

PMID: 38344571 PMC: 10858980. DOI: 10.7759/cureus.52139.

References

Albanesi C, Scarponi C, Cavani A, Federici M, Nasorri F, Girolomoni G . Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. J Invest Dermatol. 2000; 115(1):81-7. DOI: 10.1046/j.1523-1747.2000.00041.x. View

Ruckert R, Asadullah K, Seifert M, Budagian V, Arnold R, Trombotto C . Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis?. J Immunol. 2000; 165(4):2240-50. DOI: 10.4049/jimmunol.165.4.2240. View

Mease P, GOFFE B, Metz J, VanderStoep A, Finck B, Burge D . Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000; 356(9227):385-90. DOI: 10.1016/S0140-6736(00)02530-7. View

Abrams J, Kelley S, Hayes E, Kikuchi T, Brown M, Kang S . Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med. 2000; 192(5):681-94. PMC: 2193278. DOI: 10.1084/jem.192.5.681. View

Gottlieb A, Lebwohl M, Shirin S, Sherr A, Gilleaudeau P, Singer G . Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol. 2000; 43(4):595-604. DOI: 10.1067/mjd.2000.107945. View

Bonish B, Jullien D, Dutronc Y, Huang B, Modlin R, Spada F . Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol. 2000; 165(7):4076-85. DOI: 10.4049/jimmunol.165.7.4076. View

Nickoloff B, Bonish B, Huang B, Porcelli S . Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Dermatol Sci. 2000; 24(3):212-25. DOI: 10.1016/s0923-1811(00)00120-1. View

Nickoloff B . Creation of psoriatic plaques: the ultimate tumor suppressor pathway. A new model for an ancient T-cell-mediated skin disease. Viewpoint. J Cutan Pathol. 2001; 28(2):57-64. DOI: 10.1034/j.1600-0560.2001.280201.x. View

BLUMBERG H, Conklin D, Xu W, Grossmann A, Brender T, Carollo S . Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell. 2001; 104(1):9-19. DOI: 10.1016/s0092-8674(01)00187-8. View

10.

Bromley S, BURACK W, Johnson K, Somersalo K, Sims T, Sumen C . The immunological synapse. Annu Rev Immunol. 2001; 19:375-96. DOI: 10.1146/annurev.immunol.19.1.375. View

11.

Krueger G, Koo J, Lebwohl M, Menter A, Stern R, Rolstad T . The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001; 137(3):280-4. View

12.

Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S . Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001; 7(6):687-92. DOI: 10.1038/89058. View

13.

Hugot J, Chamaillard M, Zouali H, Lesage S, Cezard J, Belaiche J . Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411(6837):599-603. DOI: 10.1038/35079107. View

14.

Ogura Y, Bonen D, Inohara N, Nicolae D, Chen F, Ramos R . A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001; 411(6837):603-6. DOI: 10.1038/35079114. View

15.

Scheinfeld N . Adalimumab (HUMIRA): a review. J Drugs Dermatol. 2003; 2(4):375-7. View

16.

Rahman P, Bartlett S, Siannis F, Pellett F, Farewell V, Peddle L . CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am J Hum Genet. 2003; 73(3):677-81. PMC: 1180694. DOI: 10.1086/378076. View

17.

Kumar S, Boehm J, Lee J . p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov. 2003; 2(9):717-26. DOI: 10.1038/nrd1177. View

18.

Steed P, Tansey M, Zalevsky J, Zhukovsky E, Desjarlais J, Szymkowski D . Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science. 2003; 301(5641):1895-8. DOI: 10.1126/science.1081297. View

19.

Changelian P, Flanagan M, Ball D, Kent C, Magnuson K, Martin W . Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003; 302(5646):875-8. DOI: 10.1126/science.1087061. View

20.

Villadsen L, Schuurman J, Beurskens F, Dam T, Dagnaes-Hansen F, Skov L . Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest. 2003; 112(10):1571-80. PMC: 259129. DOI: 10.1172/JCI18986. View